Perceptive Advisors LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Perceptive Advisors LLC disclosed 112 US equity positions worth $5.5bn in its Q4 2025 13F filing. The largest position was PRAX at 10.8% of the reported book, followed by CELC and RYTM. Against the Q3 2025 filing, it opened 6 new positions, added to 27 and reduced 10 among the top 50 holdings.
What did Perceptive Advisors LLC own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 10.8% | $588.3m | 1,995,986 | 28% | added |
| 2 | CELC CELCUITY INC | Healthcare | 5.8% | $315.2m | 3,160,200 | 7% | added |
| 3 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 5.0% | $272.6m | 2,546,391 | -99% | reduced |
| 4 | ASND ASCENDIS PHARMA A/S | Healthcare | 4.2% | $230.6m | 1,081,421 | -1% | reduced |
| 5 | APGE APOGEE THERAPEUTICS INC | Healthcare | 3.2% | $175.9m | 2,330,651 | 72% | added |
| 6 | ROIV ROIVANT SCIENCES LTD | Healthcare | 3.2% | $173.3m | 7,985,461 | 8% | added |
| 7 | NUVALENT INC | 3.1% | $167.5m | 1,665,105 | 7% | added | |
| 8 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 3.0% | $163.5m | 4,278,180 | 13% | added |
| 9 | EXK EXACT SCIENCES CORP | Basic Materials | 2.2% | $121.9m | 1,200,487 | 158% | added |
| 10 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.2% | $117.9m | 1,350,425 | 31% | added |
| 11 | INBX INHIBRX BIOSCIENCES INC | 2.1% | $114.8m | 1,452,707 | 9% | added | |
| 12 | EWTX EDGEWISE THERAPEUTICS | 2.0% | $110.6m | 4,457,974 | 17% | added | |
| 13 | IMTX IMMATICS N.V | Healthcare | 2.0% | $109.0m | 10,383,456 | 11% | added |
| 14 | SYRE SPYRE THERAPEUTICS INC | 1.8% | $100.5m | 3,069,225 | 150% | added | |
| 15 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.8% | $100.1m | 8,284,882 | -7% | reduced |
| 16 | ACLXGBX ARCELLX INC | 1.8% | $95.6m | 1,466,071 | -41% | reduced | |
| 17 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.7% | $94.7m | 3,042,703 | 108% | added |
| 18 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.7% | $93.3m | 979,000 | 216% | added |
| 19 | AM6 AMICUS THERAPEUTICS INC | 1.7% | $90.7m | 6,370,851 | 0% | held | |
| 20 | ZYME ZYMEWORKS INC | Healthcare | 1.6% | $85.9m | 3,261,850 | 56% | added |
| 21 | CATBUSD ASTRIA THERAPEUTICS INC | 1.6% | $84.9m | 6,485,420 | 0% | held | |
| 22 | MGTX MEIRAGTX HLDGS PLC | 1.5% | $82.1m | 10,326,103 | -18% | reduced | |
| 23 | AORT ARTIVION INC | Healthcare | 1.4% | $78.6m | 1,722,290 | -15% | reduced |
| 24 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.3% | $73.0m | 2,917,634 | -6% | reduced | |
| 25 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.2% | $68.0m | 3,478,944 | 544% | added |
| 26 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.2% | $67.5m | 3,555,877 | 151% | added |
| 27 | SLDB SOLID BIOSCIENCES INC | Healthcare | 1.2% | $66.7m | 11,833,539 | 0% | held |
| 28 | BLTE BELITE BIO INC | Healthcare | 1.2% | $66.3m | 414,239 | 732% | added |
| 29 | ABVX ABIVAX SA | 1.1% | $61.8m | 458,343 | 18% | added | |
| 30 | IVVD INVIVYD INC | Healthcare | 1.0% | $53.8m | 21,785,166 | – | new |
| 31 | ENGENE HOLDINGS INC | 1.0% | $53.0m | 5,869,076 | 180% | added | |
| 32 | RGEN REPLIGEN CORP | Healthcare | 0.9% | $51.7m | 315,541 | 17% | added |
| 33 | IMVT IMMUNOVANT INC | Healthcare | 0.9% | $50.7m | 1,994,890 | 26% | added |
| 34 | ISRG INTUITIVE SURGICAL INC | Healthcare | 0.9% | $49.8m | 87,919 | 69% | added |
| 35 | SION SIONNA THERAPEUTICS INC | 0.9% | $48.5m | 1,179,098 | 0% | held | |
| 36 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 0.9% | $47.0m | 331,050 | -26% | reduced |
| 37 | DHR DANAHER CORPORATION | Healthcare | 0.8% | $45.8m | 200,000 | – | new |
| 38 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.8% | $44.8m | 1,476,501 | 16% | added |
| 39 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.8% | $41.2m | 9,680,185 | 0% | held |
| 40 | OMDA OMADA HEALTH INC | Healthcare | 0.7% | $37.8m | 2,396,330 | 0% | held |
| 41 | CDTX CIDARA THERAPEUTICS INC | 0.7% | $36.5m | 165,131 | – | new | |
| 42 | IRON DISC MEDICINE INC | Healthcare | 0.7% | $35.8m | 450,743 | – | new |
| 43 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 0.6% | $35.1m | 449,290 | 0% | held |
| 44 | PEN PENUMBRA INC | Healthcare | 0.6% | $34.4m | 110,529 | -50% | reduced |
| 45 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 0.6% | $31.8m | 1,784,393 | 1049% | added |
| 46 | CAI CARIS LIFE SCIENCES INC | Healthcare | 0.6% | $30.7m | 1,136,206 | 3% | added |
| 47 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 0.5% | $28.9m | 170,000 | – | new |
| 48 | PALI PALISADE BIO INC | Healthcare | 0.5% | $28.3m | 12,050,000 | – | new |
| 49 | RAPT RAPT THERAPEUTICS INC | 0.5% | $28.0m | 825,890 | 349% | added | |
| 50 | PVLA PALVELLA THERAPEUTICS INC NE | 0.5% | $27.9m | 266,287 | -33% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.